Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk pledges funds to support diabetes cause in Europe

Novo Nordisk pledges funds to support diabetes cause in Europe

12th November 2009

Novo Nordisk has announced that it has pledged a total of three million euros (2.71 million pounds) over the next three years to the European Foundation for the Study of Diabetes (EFSD), in a bid to support the organisation’s research into the life-threatening condition.

According to the firm, diabetes is growing rapidly in Europe and the need to understand the workings of the condition is pressing.

Non-profit institutions in Europe within any area of basic or clinical diabetes research are being welcomed to apply for funding and an announcement is set to be published in the official journal of the EFSD.

The deadline for applications is April 1st 2010.

Dr Viktor Jorgens, executive director of EFSD, stated: “The programme, which will be governed by the EFSD, will support European research into understanding the cause and treatment of all forms of diabetes.”

Last month, Novo Nordisk announced its financial results for the third quarter of 2009, revealing a 30 per cent increase in its operating profits, this figure rising to 11,714 million Danish kroner (1.411 billion pounds) during the period.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.